HB 941 would expand the role of pharmacists across several Florida health coverage programs by allowing patients and enrollees to choose an in-network pharmacist for services that are within a pharmacist’s licensed scope of practice. The bill applies this rule to the state group insurance program, Medicaid managed care and Medicaid-related coverage, individual and group health insurance policies, and health maintenance contracts. It also bars plans from denying reimbursement to in-network pharmacists when the same service would be covered if provided by a physician, physician assistant, or advanced practice registered nurse.
The bill further directs that licensed pharmacists may be counted toward network adequacy standards for provider access, but it makes clear that simply having pharmacies in a drug-benefit network does not satisfy that requirement. The measure creates new statutory sections in multiple parts of the Florida Statutes and takes effect January 1, 2026.
Impact
HB 941 would amend Florida law by creating new pharmacist-selection and reimbursement provisions in the statutes governing state employee health coverage, Medicaid, individual health insurance, group health insurance, and health maintenance organizations. It would require covered plans to recognize pharmacists as eligible in-network providers for covered services within their scope of practice and to reimburse them on the same basis as other licensed clinicians for comparable covered services. It also affects network adequacy rules by allowing pharmacists to count toward provider-access standards, which could influence how insurers and managed care plans build provider networks and document compliance.
Sentiment
Based on the bill text and the absence of recorded committee debate or votes in the provided materials, the overall sentiment appears supportive of expanding patient access to pharmacist-provided care. The measure is framed as a provider-access and reimbursement parity bill, suggesting an intent to broaden options for covered individuals rather than restrict them. No opposing arguments, amendments, or recorded votes are included in the available context.
Contention
The main potential point of contention is the bill’s expansion of reimbursement obligations for health plans and Medicaid-related managed care arrangements, which could raise concerns among insurers and plan administrators about cost, utilization, and network compliance. Another likely issue is the scope-of-practice boundary: the bill ties pharmacist reimbursement to services that would be covered if performed by physicians, physician assistants, or advanced practice registered nurses, which may prompt questions about which pharmacist services qualify and how plans will verify them. The bill also distinguishes between pharmacists and pharmacies, specifying that pharmacy participation in drug benefits alone is not enough for network adequacy, which could be significant for managed care contracting.
Relating to the regulation of pharmacists and the practice of pharmacy, including the administration of a medication and the ordering and administration of an immunization or vaccination by a pharmacist.